The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells

American Journal of Transplantation

Volumn 12, Issue 10, 2012, Pages 2588-2600

  Magee, C N ^a   Boenisch, O ^a   Najafian, N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alloreactive T cells; costimulatory molecules; T cell development

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ALLOIMMUNITY; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; EFFECTOR CELL; HELPER CELL; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TFH CELL; TH1 CELL; TH17 CELL; TH2 CELL; TH9 CELL;

EID: 84867098819     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04180.x     Document Type: Review

References (136)

1. Sharpe AH,. Mechanisms of costimulation. Immunol Rev 2009; 229: 5-11.
2. Li XC, Rothstein DM, Sayegh MH,. Costimulatory pathways in transplantation: Challenges and new developments. Immunol Rev 2009; 229: 271-293.
3. Pepper M, Jenkins MK,. Origins of CD4(+) effector and central memory T cells. Nat Immunol 2011; 12: 467-471.
4. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA,. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev 2011; 241: 180-205.
5. Zhou L, Chong MM, Littman DR,. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30: 646-655.
6. Dardalhon V, Awasthi A, Kwon H, et al,. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9 +IL-10 +Foxp3(-) effector T cells. Nat Immunol 2008; 9: 1347-1355.
7. Chen W, Jin W, Hardegen N, et al,. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886.
8. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H,. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005; 6: 1219-1227.
9. Veldhoen M, Uyttenhove C, van Snick J, et al,. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008; 9: 1341-1346.
10. Tao X, Constant S, Jorritsma P, Bottomly K,. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. J Immunol 1997; 159: 5956-5963.
11. Boyton RJ, Altmann DM,. Is selection for TCR affinity a factor in cytokine polarization? Trends Immunol 2002; 23: 526-529.
12. O'Shea JJ, Paul WE,. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010; 327: 1098-1102.
13. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA,. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009; 21: 281-285.
14. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al,. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10: 1000-1007.
15. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL,. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
16. Mariotti J, Foley J, Ryan K, et al,. Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood 2008; 112: 4765-4775.
17. Strom TB, Koulmanda M,. Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol 2009; 20: 1677-1680.
18. Zygmunt B, Veldhoen M,. T helper cell differentiation more than just cytokines. Adv Immunol 2011; 109: 159-196.
19. Ford ML, Larsen CP,. Translating costimulation blockade to the clinic: Lessons learned from three pathways. Immunol Rev 2009; 229: 294-306.
20. Larsen CP, Elwood ET, Alexander DZ, et al,. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438.
21. Larsen CP, Alexander DZ, Hollenbaugh D, et al,. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61: 4-9.
22. Kenyon NS, Chatzipetrou M, Masetti M, et al,. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 1999; 96: 8132-8137.
23. Kirk AD, Burkly LC, Batty DS, et al,. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693.
24. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA,. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci U S A 1996; 93: 13967-13972.
25. Durham MM, Bingaman AW, Adams AB, et al,. Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1-4.
26. Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW,. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: Implications for tolerance induction. Transplantation 2000; 70: 415-419.
27. Sho M, Sandner SE, Najafian N, et al,. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002; 236: 667-675.
28. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB,. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
29. Andre P, Prasad KS, Denis CV, et al,. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247-252.
30. Adams AB, Shirasugi N, Jones TR, et al,. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174: 542-550.
31. McIntire JJ, Umetsu SE, Akbari O, et al,. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001; 2: 1109-1116.
32. Umetsu SE, Lee WL, McIntire JJ, et al,. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol 2005; 6: 447-454.
33. Xiao S, Najafian N, Reddy J, et al,. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med 2007; 204: 1691-1702.
34. Degauque N, Mariat C, Kenny J, et al,. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest 2008; 118: 735-741.
35. Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, Umetsu DT,. The costimulatory role of TIM molecules. Immunol Rev 2009; 229: 259-270.
36. Ueno T, Habicht A, Clarkson MR, et al,. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 2008; 118: 742-751.
37. Xiao L, Fu ZR, Liu F, et al,. Suppression of allograft rejection by Tim-1-Fc through cross-linking with a novel Tim-1 binding partner on T cells. PLoS One 2011; 6: e21697.
38. Alegre ML, Noel PJ, Eisfelder BJ, et al,. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996; 157: 4762-4770.
39. Walunas TL, Bakker CY, Bluestone JA,. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-2550.
40. Paterson AM, Vanguri VK, Sharpe AH,. SnapShot: B7/CD28 costimulation. Cell 2009; 137: 974-4 e1.
41. Wing K, Onishi Y, Prieto-Martin P, et al,. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
42. Qureshi OS, Zheng Y, Nakamura K, et al,. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332: 600-603.
43. Baliga P, Chavin KD, Qin L, et al,. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation. 1994; 58: 1082-1090.
44. Azuma H, Chandraker A, Nadeau K, et al,. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A 1996; 93: 12439-12444.
45. Sayegh MH, Zheng XG, Magee C, Hancock WW, Turka LA,. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 1997; 64: 1646-1650.
46. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
47. Sabatos CA, Chakravarti S, Cha E, et al,. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003; 4: 1102-1110.
48. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH,. TIM genes: A family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235: 172-189.
49. Zhu C, Anderson AC, Schubart A, et al,. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-1252.
50. Sanchez-Fueyo A, Tian J, Picarella D, et al,. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003; 4: 1093-1101.
51. Hastings WD, Anderson DE, Kassam N, et al,. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009; 39: 2492-2501.
52. Boenisch O, D'Addio F, Watanabe T, et al,. TIM-3: A novel regulatory molecule of alloimmune activation. J Immunol 2010; 185: 5806-5819.
53. Yang J, Riella LV, Chock S, et al,. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 2011; 187: 1113-1119.
54. Riella LV, Watanabe T, Sage PT, et al,. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant 2011; 11: 832-840.
55. Ozkaynak E, Wang L, Goodearl A, et al,. Programmed death-1 targeting can promote allograft survival. J Immunol. 2002; 169: 6546-6553.
56. Ito T, Ueno T, Clarkson MR, et al,. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol 2005; 174: 6648-6656.
57. Yang J, Popoola J, Khandwala S, et al,. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 2008; 117: 660-669.
58. Gao W, Demirci G, Strom TB, Li XC,. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003; 76: 994-999.
59. Sandner SE, Clarkson MR, Salama AD, et al,. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005; 174: 3408-3415.
60. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ,. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
61. Lane P,. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med 2000; 191: 201-206.
62. Waaga AM, Gasser M, Kist-van Holthe JE, et al,. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest 2001; 107: 909-916.
63. Tay SS, Plain KM, Bishop GA,. Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant 2009; 14: 16-22.
64. Piccotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK,. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation 1997; 63: 619-624.
65. Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA,. CD28 costimulation promotes the production of Th2 cytokines. J Immunol 1997; 158: 658-665.
66. Rodriguez-Palmero M, Hara T, Thumbs A, Hunig T,. Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo. Eur J Immunol 1999; 29: 3914-3924.
67. Laskowski IA, Pratschke J, Wilhelm MJ, et al,. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002; 13: 519-527.
68. Poirier N, Azimzadeh AM, Zhang T, et al,. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Trans Med 2010; 2: 17ra10.
69. So T, Song J, Sugie K, Altman A, Croft M,. Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment. Proc Natl Acad Sci U S A 2006; 103: 3740-3745.
70. Ohshima Y, Yang LP, Uchiyama T, et al,. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 1998; 92: 3338-3345.
71. Burrell BE, Lu G, Li XC, Bishop DK,. OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade. J Immunol 2009; 182: 379-390.
72. Yuan X, Salama AD, Dong V, et al,. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 2003; 170: 2949-2955.
73. Demirci G, Amanullah F, Kewalaramani R, et al,. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004; 172: 1691-1698.
74. Salama AD, Yuan X, Nayer A, et al,. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant 2003; 3: 390-395.
75. Harada H, Salama AD, Sho M, et al,. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 2003; 112: 234-243.
76. Ozkaynak E, Gao W, Shemmeri N, et al,. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591-596.
77. Sperling AI, Bluestone JA,. ICOS costimulation: It's not just for TH2 cells anymore. Nat Immunol 2001; 2: 573-574.
78. Park H, Li Z, Yang XO, et al,. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
79. Watanabe M, Watanabe S, Hara Y, et al,. ICOS-mediated costimulation on Th2 differentiation is achieved by the enhancement of IL-4 receptor-mediated signaling. J Immunol 2005; 174: 1989-1996.
80. Takahashi N, Matsumoto K, Saito H, et al,. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol 2009; 182: 5515-5527.
81. Yang PC, Xing Z, Berin CM, et al,. TIM-4 expressed by mucosal dendritic cells plays a critical role in food antigen-specific Th2 differentiation and intestinal allergy. Gastroenterology 2007; 133: 1522-1533.
82. Feng BS, Chen X, He SH, et al,. Disruption of T-cell immunoglobulin and mucin domain molecule (TIM)-1/TIM4 interaction as a therapeutic strategy in a dendritic cell-induced peanut allergy model. J Allergy Clin Immunol 2008; 122: 55-61, e1-e7.
83. Chakravarti S, Sabatos CA, Xiao S, et al,. Tim-2 regulates T helper type 2 responses and autoimmunity. J Exp Med 2005; 202: 437-444.
84. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al,. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133-3144.
85. Agorogiannis EI, Regateiro FS, Howie D, Waldmann H, Cobbold SP,. Th17 cells induce a distinct graft rejection response that does not require IL-17A. Am J Transplant 2012; 12: 835-845.
86. Chadha R, Heidt S, Jones ND, Wood KJ,. Th17: Contributors to allograft rejection and a barrier to the induction of transplantation tolerance? Transplantation 2011; 91: 939-945.
87. Ying H, Yang L, Qiao G, et al,. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol 2010; 185: 1375-1378.
88. Bouguermouh S, Fortin G, Baba N, Rubio M, Sarfati M,. CD28 co-stimulation down regulates Th17 development. PLoS One 2009; 4: e5087.
89. Bauquet AT, Jin H, Paterson AM, et al,. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol 2009; 10: 167-175.
90. Paulos CM, Carpenito C, Plesa G, et al,. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Trans Med 2010; 2: 55ra78.
91. Yuan X, Ansari MJ, D'Addio F, et al,. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A 2009; 106: 10734-10739.
92. Cao W, Ryan M, Buckley D, O'Connor R, Clarkson MR,. Tim-4 inhibition of T-cell activation and T helper type 17 differentiation requires both the immunoglobulin V and mucin domains and occurs via the mitogen-activated protein kinase pathway. Immunology 2011; 133: 179-189.
93. Iezzi G, Sonderegger I, Ampenberger F, Schmitz N, Marsland BJ, Kopf M,. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci U S A 2009; 106: 876-881.
94. Li J, Li L, Shang X, et al,. Negative regulation of IL-17 production by OX40/OX40L interaction. Cell Immunol 2008; 253: 31-37.
95. Weinberg AD, Wegmann KW, Funatake C, Whitham RH,. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999; 162: 1818-1826.
96. Yoshioka T, Nakajima A, Akiba H, et al,. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000; 30: 2815-2823.
97. Tai X, Cowan M, Feigenbaum L, Singer A,. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005; 6: 152-162.
98. Tang Q, Henriksen KJ, Boden EK, et al,. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003; 171: 3348-3352.
99. Salomon B, Lenschow DJ, Rhee L, et al,. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25 +immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440.
100. Yang J, Riella LV, Boenisch O, et al,. Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model. Am J Transplant 2009; 9: 2837-2844.
101. Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ,. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol 2008; 181: 2285-2291.
102. Bour-Jordan H, Bluestone JA,. Regulating the regulators: Costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009; 229: 41-66.
103. Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu XZ,. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood 2011; 117: 3096-3103.
104. Lakkis FG, Konieczny BT, Saleem S, et al,. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997; 158: 2443-2448.
105. Beyersdorf N, Gaupp S, Balbach K, et al,. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202: 445-455.
106. Hunig T,. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 2007; 95: 111-148.
107. Suntharalingam G, Perry MR, Ward S, et al,. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
108. Mellor AL, Munn DH,. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774.
109. Larsen CP, Pearson TC, Adams AB, et al,. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
110. Riella LV, Liu T, Yang J, et al,. Deleterious Effect of CTLA4-Ig on a Treg-Dependent Transplant Model. Am J Transplant 2012; 12: 846-855.
111. Bluestone JA, Liu W, Yabu JM, et al,. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086-2096.
112. De Serres SA, Sayegh MH, Najafian N,. Immunosuppressive drugs and Tregs: A critical evaluation! Clin J Am Soc Nephrol 2009; 4: 1661-1669.
113. Francisco LM, Salinas VH, Brown KE, et al,. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029.
114. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al,. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 2003; 171: 1272-1277.
115. Wang F, He W, Yuan J, et al,. Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol 2008; 19: 12-19.
116. He W, Fang Z, Wang F, et al,. Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice. Transplantation 2009; 88: 782-790.
117. Bushell A, Wood K,. GITR ligation blocks allograft protection by induced CD25+CD4 +regulatory T cells without enhancing effector T-cell function. Am J Transplant 2007; 7: 759-768.
118. So T, Croft M,. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J Immunol 2007; 179: 1427-1430.
119. Vu MD, Xiao X, Gao W, et al,. OX40 costimulation turns off Foxp3 +Tregs. Blood 2007; 110: 2501-2510.
120. Kroemer A, Xiao X, Vu MD, et al,. OX40 controls functionally different T cell subsets and their resistance to depletion therapy. J Immunol 2007; 179: 5584-5591.
121. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG,. Follicular helper T cells: Lineage and location. Immunity 2009; 30: 324-335.
122. King C,. New insights into the differentiation and function of T follicular helper cells. Nat Rev Immunol 2009; 9: 757-766.
123. Qi H, Cannons JL, Klauschen F, Schwartzberg PL, Germain RN,. SAP-controlled T-B cell interactions underlie germinal centre formation. Nature 2008; 455: 764-769.
124. Akiba H, Takeda K, Kojima Y, et al,. The role of ICOS in the CXCR5 +follicular B helper T cell maintenance in vivo. J Immunol 2005; 175: 2340-2348.
125. Choi YS, Kageyama R, Eto D, et al,. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011; 34: 932-946.
126. Bossaller L, Burger J, Draeger R, et al,. ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells. J Immunol 2006; 177: 4927-4932.
127. Grimbacher B, Hutloff A, Schlesier M, et al,. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003; 4: 261-268.
128. Linterman MA, Rigby RJ, Wong R, et al,. Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS. Immunity 2009; 30: 228-241.
129. Fazilleau N, McHeyzer-Williams LJ, Rosen H, McHeyzer-Williams MG,. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol 2009; 10: 375-384.
130. Yu D, Rao S, Tsai LM, et al,. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 2009; 31: 457-468.
131. Haynes NM, Allen CD, Lesley R, Ansel KM, Killeen N, Cyster JG,. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J Immunol 2007; 179: 5099-5108.
132. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ,. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 2010; 11: 535-542.
133. Hams E, McCarron MJ, Amu S, et al,. Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells. J Immunol 2011; 186: 5648-5655.
134. Staudt V, Bothur E, Klein M, et al,. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010; 33: 192-202.
135. Hutloff A, Dittrich AM, Beier KC, et al,. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397: 263-266.
136. Keir ME, Butte MJ, Freeman GJ, Sharpe AH,. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008; 26: 677-704.